I. INTRODUCTION
Treatment of hepatitis C virus (HCV) infection includes treatment-naïve patients and patients with treatment experience, either interferon, peginterferon plus ribavirin or any direct-acting antivirals (DAA). Recommended regimens are those that are favored for most chronic hepatitis C (CHC) patients in a given group, based on optimal efficacy, favored tolerability and adverse effect profiles and duration. Alternative regimens are also effective but relative to recommended regimes because of having potential disadvantages, limitations for use in such populations, or less supporting data than recommended regimens.
The following treatment regimens are listed in order of level of evidence. Some were reimbursed in Turkey. According to unpublished data, until today, in Turkey, sustained virological response (SVR) rate of either a combination of ledipasvir/sofosbuvir or a combination of paritaprevir/ritonavir/ombitasvir with dasabuvir with/without ribavirin is more than 90% in CHC patients with/without cirrhosis.
II. TREATMENT FOR PATIENTS INFECTED WITH GENOTYPE 1

II.A. Treatment for Patients Infected with Genotype 1 (G1)
There are several DAA regimes are recommended for treatment-naïve patients infected with genotype 1. The recommended regimens were changed based on the HCV subtype, baseline NS5A status and the presence or absence of compensated cirrhosis were effect on. CHC patients infected with genotype 1a may have a higher virological failure rates in comparison with genotype 1b infection.
II. HCV Treatment in G1 Patients
There are several recommended regimens with comparable efficacy. Some were on market in Turkey*.
II.A. Treatment in G1a Patients
II.A.1 Treatment-Naive G1a Patients
II.A.1.a Treatment for Patients without Cirrhosis
• • Hepatitis C virus and HBV co-infected patients should be treated as well as patients with chronic HCV monoinfection.
VII.C. Patients with HIV Co-Infections
Liver-related morbidity and mortality and overall mortality are more common in HCV and HIV (Human immunodeficiency virus)-co-infected patients than HCV-monoinfected patients.
HIV infection is associated with advance hepatic fibrosis and cirrhosis in co-infected patients. The treatment of CHC patients with HIV co-infections is not different than other CHC patients.
The adverse events of antiviral therapy for HCV infection is similar to those observed with HCV monoinfection. The most important point in these co-infected patients is to pay attention to drug-drug interactions that can occur between DAAs and antiretroviral agents. Therefore, for every patient to candidate receiving these treatments, the drug interactions, adverse effects and dose adjustments should be investigated. Physicians should be collaborated with the HIV expert. The presence of HIV co-infection is not a contraindication for LT. 
VII.D. Patients with
VIII. ACUTE HEPATITIS C TREATMENT
Acute HCV infection spontaneously clears in 20% to 50% of infected individuals. It occurs within six months of the estimated time of acute infection. In past, antiviral treatment with interferons was initiated as early as possible in order to prevent chronicity of acute infection. Currently, there is no consensus regarding when to start DAAs or treatment duration in the treatment of patients with acute HCV infection. Since high efficacy and safety profile of DAAs, it seems to be that no rush is necessary to initiate treatment early. Antiviral therapy is not recommended in spontaneous seroconvertion period. The appropriate time frame to initiate treatment should be at the start of serum ALT elevation. The same treatment approaches for CHC which is described above is recommended.
• The treatment duration should be extended, up to 12 weeks in patients with HIV co-infection or in patients with high viral load (HCV RNA level >1 million IU/mL).
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